KRAS and ovarian serous adenocarcinoma: NGS confirmed the presence of c.733G>A (p.Gly245Ser) mutation in TP53 gene in OVPA8 cells, and excluded mutations typical for low-grade serous ovarian cancers, i.e., in the KRAS, BRAF, and ERBB2 genes.